BMC Gastroenterol
- JAFREE SR, Naveed A, Ahsan H, Burhan SK, et al
Predictors of health-seeking behavior in patients with chronic liver disease and
a comparison of health-seeking based on patient-type.
BMC Gastroenterol. 2025;25:642.
- ZHANG Y, Luo M, Ming Y
Global burden of cirrhosis and other chronic liver diseases caused by specific
etiologies from 1990 to 2021.
BMC Gastroenterol. 2025;25:641.
Br J Surg
- REESE T, Bjork D, Longva AMH, Kiim KS, et al
Oncological safety of portal vein embolization without prior tumour clearance in
the future liver remnant followed by one-stage hepatectomy for bilateral
colorectal liver metastases.
Br J Surg. 2025;112:znaf198.
Eur J Pediatr
- LIN DC, Hou JY, Tseng CK, Tsai PS, et al
The changes in imaging following proton beam therapy for pediatric
hepatoblastoma.
Eur J Pediatr. 2025;184:626.
Gastroenterology
- FOX D, Xie J, Burwinkel JL, Adams JM, et al
Adeno-associated Virus-mediated Silencing of Sox4 Leads to Long-Term Amelioration
of Liver Phenotypes in Mouse Models of Alagille Syndrome.
Gastroenterology. 2025;169:1000-1016.
J Gastroenterol
- FUJII H, Uchida-Kobayashi S, Kanamori A, Nadatani Y, et al
Defining optimal fatty liver index thresholds for MASLD and MetALD using
controlled attenuation parameter as reference.
J Gastroenterol. 2025;60:1296-1309.
- LEE J, Cha JH, Cho HS, Yang K, et al
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced
fibrosis in MASLD: a prospective genotype-phenotype study.
J Gastroenterol. 2025;60:1284-1295.
J Hepatol
- OCHOA-ALLEMANT P, Hubbard RA, Kaplan DE, Serper M, et al
Cause-specific mortality in patients with steatotic liver disease in the United
States.
J Hepatol. 2025;83:860-869.
- ISBISTER G, Chiew A, Buckley N, Harris K, et al
A non-inferiority randomised controlled trial of a Shorter Acetylcysteine Regimen
for Paracetamol Overdose - the SARPO trial.
J Hepatol. 2025 May 23:S0168-8278(25)02206-8. doi: 10.1016/j.jhep.2025.
- DIAZ LA, Alazawi W, Agrawal S, Arab JP, et al
High inherited risk predicts age-associated increases in fibrosis in patients
with MASLD.
J Hepatol. 2025;83:849-859.
- RIMASSA L, Chan SL, Sangro B, Lau G, et al
Five-year overall survival update from the HIMALAYA study of tremelimumab plus
durvalumab in unresectable HCC.
J Hepatol. 2025;83:899-908.
Oncogene
- TSUCHIYA H, Hanaki T, Sakabe T, Tokuyasu N, et al
Immune evasion from macrophages by NEAT1-induced CD24 in liver cancer.
Oncogene. 2025;44:3652-3664.
PLoS One
- YUAN J, Chen Z, Gu Y, Liang Y, et al
Effects of alcohol consumption on the prevalence and incidence of non-alcoholic
fatty liver disease: A systematic review and meta-analysis.
PLoS One. 2025;20:e0330105.
Proc Natl Acad Sci U S A
- YUAN Y, Niu Y, Huang Z, Shi Y, et al
USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in
hepatocellular carcinoma.
Proc Natl Acad Sci U S A. 2025;122:e2510576122.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016